Andrew Grethlein

Inspiration Biopharmaceuticals, Inc. produces intravenous recombinant therapies and develops non-invasive applications. It offers its products for the hemophilia community. The company was founded by Scott Donnelly Martin and John Read Taylor, Jr. on April 28, 2006 and is headquartered in Boston, MA.

The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc.

Elan Corp. Plc is a neuroscience focused biotechnology company. The company engages in research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis. It was founded in December 1969 and is headquartered in Dublin, Ireland.

Athena Neurosciences LLC operates as a research-based pharmaceutical company committed to the field of neurology. It develops therapeutic and diagnostic products. The company was founded by David Rowley-Jones, Larry C. Fritz, and Larry A. Bock in 1986 and is headquartered in Allegan, MI.

Ipsen International GmbH manufactures and distributes furnaces and plant systems. Its products include sealed quench furnaces; chamber and multi-purpose chamber furnaces; horizontal and vertical furnaces; EcoFire system; HydroNit Sensor; HybridCarb; and EndoSave system. The firm also provides software processes such as Carb-o-Prof 4.0, AutoMag, Vacu-Prof, and Conti-Control. The company was founded by Harold Ipsen in 1957 and is headquartered in Kleve, Germany.